ArticleEuropean journal of medical research2025
Transplantation of miR-216a-5p-overexpressing mesenchymal stem cells encapsulated in a thermosensitive hydrogel promotes functional recovery in a rat model of spinal cord injury.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overcoming Barriers to Axonal Regeneration in Spinal Cord Injury: Mechanistic Insights and Therapeutic Frontiers.CNS neuroscience & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
To evaluate the therapeutic efficacy of mesenchymal stem cells (MSCs) overexpressing miR-216a-5p delivered via a thermosensitive hydrogel in a rat model of spinal cord injury (SCI). A thermosensitive hydrogel was engineered to encapsulate MSCs overexpressing miR-216a-5p (MSC-miR-216a-5p). The hydrogel-cell construct was characterized for its physical properties and transplanted into rats with contusion SCI. Functional recovery was assessed using the Basso, Beattie, and Bresnahan (BBB) locomotor scale, mechanical withdrawal threshold (MWT), and thermal withdrawal latency (TWL). Inflammatory responses were evaluated by measuring pro-inflammatory cytokine levels. The engineered hydrogel demonstrated suitable mechanical properties, temperature-dependent swelling, and controlled degradation behavior. Rats treated with hydrogel-encapsulated MSC-miR-216a-5p showed significantly improved functional recovery, evidenced by higher BBB, MWT, and TWL scores than control groups. The treatment effectively modulated the inflammatory response by reducing pro-inflammatory cytokine levels. Mechanistic studies identified GPBP1 as a direct target of miR-216a-5p, mediating the observed neuroprotective and anti-inflammatory effects. The combination of miR-216a-5p-overexpressing MSCs with a thermosensitive hydrogel delivery system represents a promising therapeutic strategy for SCI treatment. This approach promotes functional recovery and modulates inflammatory responses through GPBP1 targeting, offering potential for clinical translation in SCI therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.